307 related articles for article (PubMed ID: 20039942)
1. Different responses to interferon beta-1b treatment in patients with neuromyelitis optica and multiple sclerosis.
Uzawa A; Mori M; Hayakawa S; Masuda S; Kuwabara S
Eur J Neurol; 2010 May; 17(5):672-6. PubMed ID: 20039942
[TBL] [Abstract][Full Text] [Related]
2. Interferon-beta(1b) treatment in neuromyelitis optica.
Tanaka M; Tanaka K; Komori M
Eur Neurol; 2009; 62(3):167-70. PubMed ID: 19590215
[TBL] [Abstract][Full Text] [Related]
3. Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination.
Warabi Y; Matsumoto Y; Hayashi H
J Neurol Sci; 2007 Jan; 252(1):57-61. PubMed ID: 17125797
[TBL] [Abstract][Full Text] [Related]
4. Interferon beta-1b is effective in Japanese RRMS patients: a randomized, multicenter study.
Saida T; Tashiro K; Itoyama Y; Sato T; Ohashi Y; Zhao Z;
Neurology; 2005 Feb; 64(4):621-30. PubMed ID: 15728282
[TBL] [Abstract][Full Text] [Related]
5. Comparison of injection site pain and injection site reactions in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a or 1b.
Baum K; O'Leary C; Coret Ferrer F; Klímová E; Procházková L; Bugge J;
Mult Scler; 2007 Nov; 13(9):1153-60. PubMed ID: 17967843
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-17-secreting T cells in neuromyelitis optica and multiple sclerosis during relapse.
Wang HH; Dai YQ; Qiu W; Lu ZQ; Peng FH; Wang YG; Bao J; Li Y; Hu XQ
J Clin Neurosci; 2011 Oct; 18(10):1313-7. PubMed ID: 21795048
[TBL] [Abstract][Full Text] [Related]
7. Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis.
Gajofatto A; Bacchetti P; Grimes B; High A; Waubant E
Mult Scler; 2009 Jan; 15(1):50-8. PubMed ID: 18922831
[TBL] [Abstract][Full Text] [Related]
8. Interferon beta-1b modulates serum sVCAM-1 levels in primary progressive multiple sclerosis.
Bitsch A; Bahner D; Wachter C; Elitok E; Bogumil T; Dressel A; Polak T; Tumani H; Weber F; Poser S; Kitze B
Acta Neurol Scand; 2004 Dec; 110(6):386-92. PubMed ID: 15527451
[TBL] [Abstract][Full Text] [Related]
9. IFNβ-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum.
Shimizu J; Hatanaka Y; Hasegawa M; Iwata A; Sugimoto I; Date H; Goto J; Shimizu T; Takatsu M; Sakurai Y; Nakase H; Uesaka Y; Hashida H; Hashimoto K; Komiya T; Tsuji S
Neurology; 2010 Oct; 75(16):1423-7. PubMed ID: 20826711
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the T cell receptor repertoire in the Japanese neuromyelitis optica: T cell activity is up-regulated compared to multiple sclerosis.
Warabi Y; Yagi K; Hayashi H; Matsumoto Y
J Neurol Sci; 2006 Nov; 249(2):145-52. PubMed ID: 16860825
[TBL] [Abstract][Full Text] [Related]
11. From high- to low-frequency administered interferon-beta for multiple sclerosis: a multicenter study.
Prosperini L; Mancinelli CR; Pozzilli C; Grasso MG; Clemenzi A; Collorone S; Pontecorvo S; Francia A; Villani V; Koudriavtseva T; Buttari F; Centonze D; Di Battista G; Frisullo G; Galgani S; Gasperini C
Eur Neurol; 2014; 71(5-6):233-41. PubMed ID: 24480868
[TBL] [Abstract][Full Text] [Related]
12. Interferon beta treatment for multiple sclerosis: persisting questions.
Goodkin DE
Mult Scler; 1996 Jul; 1(6):321-4. PubMed ID: 9345408
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic efficacy of interferon β-1b in Japanese patients with optic-spinal multiple sclerosis.
Shimizu Y; Fujihara K; Kubo S; Takahashi T; Misu T; Nakashima I; Yokoyama K; Itoyama Y; Uchiyama S
Tohoku J Exp Med; 2011 Mar; 223(3):211-4. PubMed ID: 21403431
[TBL] [Abstract][Full Text] [Related]
14. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
Togha M; Karvigh SA; Nabavi M; Moghadam NB; Harirchian MH; Sahraian MA; Enzevaei A; Nourian A; Ghanaati H; Firouznia K; Jannati A; Shekiba M
Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825
[TBL] [Abstract][Full Text] [Related]
15. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.
Cohen JA; Coles AJ; Arnold DL; Confavreux C; Fox EJ; Hartung HP; Havrdova E; Selmaj KW; Weiner HL; Fisher E; Brinar VV; Giovannoni G; Stojanovic M; Ertik BI; Lake SL; Margolin DH; Panzara MA; Compston DA;
Lancet; 2012 Nov; 380(9856):1819-28. PubMed ID: 23122652
[TBL] [Abstract][Full Text] [Related]
16. Increased plasma levels of pentraxin 3 in patients with multiple sclerosis and neuromyelitis optica.
Wang H; Wang K; Wang C; Zhong X; Qiu W; Hu X
Mult Scler; 2013 Jun; 19(7):926-31. PubMed ID: 23012252
[TBL] [Abstract][Full Text] [Related]
17. Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder?
Kim SH; Kim W; Li XF; Jung IJ; Kim HJ
Mult Scler; 2012 Oct; 18(10):1480-3. PubMed ID: 22354738
[TBL] [Abstract][Full Text] [Related]
18. Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns.
O'Rourke KE; Hutchinson M
Mult Scler; 2005 Feb; 11(1):46-50. PubMed ID: 15732266
[TBL] [Abstract][Full Text] [Related]
19. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
Schwid SR; Panitch HS
Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of interferon beta-1b for the treatment of patients with a first clinical event suggestive of multiple sclerosis.
Caloyeras JP; Zhang B; Wang C; Eriksson M; Fredrikson S; Beckmann K; Knappertz V; Pohl C; Hartung HP; Shah D; Miller JD; Sandbrink R; Lanius V; Gondek K; Russell MW
Clin Ther; 2012 May; 34(5):1132-44. PubMed ID: 22541587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
